Hypertension is an important cause of end-stage renal disease (ESRD) in the USA and in Sub-Saharan Africa. Antihypertensive therapy has led to a substantial decrease in incidence of stroke (42%) and to a lesser extent of myocardial infarction (16%), yet there has been an increase in hypertension related ESRD. In 1991, about 190 000 persons in the USA either underwent dialysis or received a transplant for ESRD. Hypertension was found to be the underlying cause in 29% of these patients, second only to diabetes mellitus (36%). Both in the USA and South Africa hypertension was found to be the most common cause of ESRD, but it is not clear whether this is related to the higher incidence and severity of hypertension in black people. Moreover blood pressure (BP) control in black patients does not
Introduction
The incidence of end-stage renal disease (ESRD) in the USA is increasing at the rate of 8% to 10% per year and poses a major national health problem. 1 In South Africa, a developing country, the number of patients on the registry of the South African Dialysis and Transplantation was 7331 patients in 1994. 2 During the last decade the incidence of ESRD due to glomerulonephritis has remained unchanged. However during the same period of time there was a 45% increase in ESRD from hypertension and diabetes. 3 This is in contrast to the trend from two major complications of hypertension, myocardial infarction and stroke, both of which decreased in incidence by about 25% in the same decade. 4, 5 In 1991 about 190 000 persons in the United States either underwent dialysis or received a transplant for ESRD. Hypertension was found to be the underlying cause in 29% of these patients, second only to diabetes (36%). In black patients, hypertension was found to be the most common cause of ESRD. Furthermore, the yearly incidence of ESRD in all renal diseases, except polycystic kidney disease, was significantly greater in black than in white patients. 6 In our study we found that hypertension caused ESRD in 32% of our black patients whereas it caused ESRD in 10% of white patients. 7 The mechanism by which hypertension damages the kidney is unknown. The two mechanisms currently postulated for the development of ESRD due to hypertension are: (1) ischaemic due to injury of the preglomerular vasculature; and (2) glomerular injury due to transmission of systemic hypertension to glomerular capillaries. [8] [9] [10] The reasons why there is no evidence of an important reduction in ESRD due to hypertension are unclear but some of the postulated mechanisms are received.
Misdiagnosis
The diagnosis of hypertensive nephrosclerosis ideally requires histological confirmation of arteriolar hyalinosis and muscular hyperplasia accompanied by various degrees of renal parenchymal damage. 8 However few patients given this diagnosis have histologic confirmation. In the absence of renal biopsy, the diagnosis should be based on: (1) a carefully taken clinical history showing normal renal function at the time of the initial diagnosis of hypertension; (2) other end-organ evidence like left ventricular hypertrophy or retinopathy; and (3) the absence of other risk factors for renal disease. Some studies show that patients diagnosed with hypertensive nephrosclerosis seldom meet these criteria. 11, 12 Hypertension is a common complication of renal disease, affecting up to 90% of ESRD patients. Thus without a careful and specific diagnosis, hypertension may mistakenly be assumed to be the cause rather than the consequence of renal failure. To complicate the issue, nephrologists are twice as likely to label a black patient as having hypertensive nephrosclerosis as a white patient when presented with identical clinical histories. 13 Schlessinger et al 11 traced the clinical data of patients referred to their institution for renal transplantation with a diagnosis and found that none of those patients for whom 'complete' data were available had either a diagnostic biopsy or enough clinical evidence to support the diagnosis. Freedman et al 14 has suggested that renal artery stenosis, intrinsic renal parenchymal diseases, microvascular diseases, and unrecognised episodes of accelerated hypertension could account for many cases diagnosed as hypertensive nephropathy.
The effect of race
For the past 30 years, several studies have shown differences in the prevalence of hypertension between black and white people. Moreover severe hypertension was present four and five times more frequently in black men and white men and women respectively. 15 There are also marked differences in the incidence of ESRD between black and white patients. 7, 16 It is not clearly delineated whether the greater susceptibility to chronic renal failure is related to their greater susceptibility to hypertension. There are studies which suggest that black subjects are more susceptible to renal injury from hypertension than white people. 17, 18 Studies have shown that blood pressure control, particularly in black patients, does not always prevent progression of renal failure. Rostand et al 19 reported a deterioration in renal function in 16% of patients with essential hypertension independent of blood pressure control. The two factors associated with this deterioration were older age and black race. Moreover, a 15-year follow-up in a population of 12 000 men with hypertension identified black race, diabetes and history of urinary tract problems as independent risk factors for development of ESRD. 20 The Multiple Risk Factor Intervention Trial (MRFIT) suggested that effective blood pressure control was associated with stable or improving renal function in non-blacks but not in blacks. 
Socio-economic status
There is a marked disparity in the prevalence and severity of hypertension between black and white patients. 22 Others include the higher prevalence of diabetes mellitus and the lower socio-economic status of black compared to white people. 23 One study found a strong association between low socioeconomic status and incidence of ESRD in both black and white Americans 24 whereas another study found this association only among whites. 25 However, socio-economic differences between black and white people may not by itself explain the higher incidence of hypertensive ESRD in black subjects, because stroke and cardiovascular mortality have decreased similarly in both ethnic groups. 26 Other studies have failed to demonstrate the variations in prevalence, severity, age at onset of hypertension, and socio-economic status to explain the difference in incidence of hypertensive nephrosclerosis between black and white patients. 27 
Physiologic differences
Black hypertensives are more likely than whites to exhibit blood pressure sensitivity to a diet high in sodium 28 and when maintained on such a diet, to show a significant decrease in effective renal plasma flow and a significant increase in calculated glomerular pressure. 29 Numerous renal, hormonal and physiologic differences have been suggested to underlie the propensity for hypertension and renal failure in blacks. These include lower kallikrein excretion rate, 30 decreased plasma dopamine ␤-hydroxylase, 31 greater plasma volume, 32 greater renal vascular resistance in the presence of decreased renal blood flow, 33 altered natriuretic response to acute volume expansion 34 and impaired maturation of kidney secondary to low birth weight, which is more common in black patients. 35 Moreover, renal biopsies performed in black patients with severe hypertension and varying degrees of renal function impairment showed that histopathologic findings differed from those in white patients with nephrosclerosis. Black patients in the USA differed in terms of lack of fibrinoid necrosis, evidence of glomerular ischaemia rather than proliferative glomerulitis and greater myointimal proliferation with deposition of mucopolysaccharides. 36 This is in contrast to the South African blacks suffering from malignant hypertension in whom fibrinoid necrosis is a feature.
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The significance of the findings
There may be findings in addition to hypertension which leads to progression of nephrosclerosis. One possibility is that the subgroup of black patients may have hypertension based on a primary renal mechanism, with hypertension being the consequence, or an associated comorbidity of underlying renal disease. 38 An alternative hypothesis is that racial differences in severity of nephrosclerosis may be due to increased production of such growth factors such as transforming growth factor and platelet-derived growth factor that promote renal scarring, which is common in blacks. 39 
The effect of blood pressure control
Another explanation is inadequate blood pressure control. The NHANES III study showed that only 25% of the hypertensive population achieved normal control of blood pressure. 40 Epidemiologic studies suggest that black subjects require blood pressure control below normotensive levels.
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hypertension is associated with an increased risk of ESRD and more aggressive treatment may be beneficial to prevent the development of ESRD.
Drug treatment
All antihypertensive drugs lower blood pressure, but different agents may affect glomerular haemodynamics in different ways (Table 1 ). Experimental data suggest that renal injury in hypertension may be due to transmission of systemic hypertension to the glomerulus. 44, 45 During antihypertensive therapy, systemic blood pressure may be reduced but glomerular capillary pressure may remain elevated. This may explain why the incidence of some cardiovascular complications such as stroke, has decreased, whereas the incidence of hypertensive nephropathy has remained high. 4, 5 In the intrarenal vasculature, angiotensin receptors are found in greater density in the efferent than in the afferent arterioles. Thus, blunting the effect of angiotensin not only lowers blood pressure, but may also reduce glomerular capillary pressure to a greater extent. Calcium channel blockers (CCB) exert preferential vasodilation of afferent arterioles and may not reduce glomerular capillary pressure as efficiently as angiotensin-converting enzyme (ACE) inhibitors.
46,47 ACE inhibitors may be more effective than ␤-blockers in slowing progression of renal failure 48 and may achieve greater reduction in proteinuria than CCB. A study with a follow-up of 3 years showed that ESRD was more frequent in those treated with CCB compared to ACE inhibitors. 49 Benazepril, an ACE inhibitor, has been shown to provide protection against the protection of renal insufficiency in patients with various renal diseases. 50 The renoprotective role of diuretics, ␣-adrenergic blockers and direct vasodilators is unclear, due to insufficient data. 51 Long-term studies are needed to determine whether antihypertensive agents which increase glomerular filtration promote or fail to arrest glomerulosclerosis. Angiotensin II causes hypertrophy and hyperplasia in both mesangial and vascular smooth muscle cells. In addition growth factors like transforming growth factors ␤ and platelet-derived growth factor promotes extracellular matrix synthesis by mesangial cells. [52] [53] [54] ACE inhibitors and angiotensin II blockers may have beneficial effects independent of their effects on blood pressure. CCB also have pathophysiologic effects independent of their hypotensive effects because they inhibit both muscle cell and mesangial cell proliferation. A combination of ACE inhibitors and CCB may provide additional renoprotection. 55 
Other factors that influence renal disease
Hypertensive renal disease may be genetically determined. Brown et al 56 has identified a gene that predisposes to hypertensive renal injury and has no apparent effect on blood pressure. It is possible that this gene or other genes are linked with the failure of the afferent arteriole to antoregulate and therefore lead to a high glomerular pressure and hyperfiltration.
Conclusion
These findings (see Table 2 ) suggest that factors other than blood pressure elevation probably cause a progression of nephrosclerosis.
